Presenting the first version of the platform
MIT CSAIL Alliances is the member-only network of companies that partner with research at the MIT Computer Science and Artificial Intelligence Laboratory (CSAIL), and its annual meeting brings those members together with CSAIL faculty, researchers, and students. On April 28, 2025, Dr. Omar Costilla Reyes announced that the Equ Healthcare team would be on the MIT campus that week to share its mission to build the future of healthcare and to explore partnerships. On April 29 he presented the first version of the Equ Healthcare platform in a lecture hall, afterward writing “Presentation done!” and thanking the organizers for the event.
The slide on screen introduced Equ as “Your Intelligent GLP-1 Medication Management Companion”: a product that works with a person’s body, data, and habits to help them lose weight, feel better, and take control of their health while taking GLP-1 medications, with a QR code and contact details for people who wanted to follow up.
What GLP-1 medication management involves
GLP-1 (glucagon-like peptide-1) medications are a class of prescription drugs used to treat type 2 diabetes and, increasingly, for weight management. They typically involve a dosing schedule, gradual increases in dose over time, and attention to side effects, so day-to-day management can be a practical burden for patients. A companion application of the kind shown on the slide aims to support that routine by combining a person’s own data with guidance. The presentation gave the CSAIL Alliances community an early look at how a data-driven companion can support those everyday routines, following the launch of the company’s first AI beta program the month before.
From CSAIL Alliances member to platform introduction
Equ Healthcare joined the MIT CSAIL Alliances member ecosystem in January 2025, which Dr. Costilla Reyes described as joining a network of industry-leading companies, new and established, that seek to innovate and partner with MIT’s research ecosystem. In March 2025 the company launched its first AI beta program for GLP-1 (Ozempic) medication management, and the annual meeting presentation followed the next month.
The platform draws on his research at MIT on program synthesis and neurosymbolic AI, which pairs learning from data with explicit reasoning so that a system’s conclusions can be inspected. The company describes its goal as AI that works alongside clinicians rather than replacing their judgment.